Market Research Logo

The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies


Attention: There is an updated edition available for this report.

Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life.

Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the following drug categories:

  • Allergy and Cold
  • Antilipidemic Agents
  • Fungal Infections
  • Gastrointestinal Drugs
  • Hair Loss Treatments
  • Migraine Therapy
  • Nonsteroidal Anti-inflammatories
  • Oral Contraceptives
  • Osteoporosis and Hormone Replacement Therapies
  • Overactive Bladder
  • Sexual Dysfunction
  • Sleep Agents
  • Smoking Cessation
  • Viral Infections
  • Others
  • Kalorama Information believes this trend of utilizing Rx to OTC will continue. There are currently 14 prescription drugs, with worldwide prescription sales exceeding $20 billion in 2006, with the potential to reach the OTC market by the year 2013.

    What are the most viable products that are candidates for Rx to OTC switches? Who are the players in the industry best suited to execute this strategy? What is the market potential for Rx to OTC in key categories? And what are the advantages and pitfalls of using this tactic in the current market? These questions and more are answered in this Kalorama Information report, the result of Moutaintop Medical's exhaustive analysis and interviews with experts in the industry.

    License Note: Kalorama Information's listed default price on its information products reflects a single user license only. Purchasing a global site license (entire company) permits multiple individuals in the company to benefit from this resource.


    • Executive Summary
      • SCOPE OF THE REPORT
        • Table Major Markets for Rx to OTC 2008 and 2010
      • METHODOLOGY
      • ISSUES AND TRENDS
    • Rx-to-OTC Product and Market Analysis
      • INTRODUCTION
        • Table Revenue, Major Rx to OTC Categories, 2008
        • Table Potential Rx-to-OTC Switches, 2008-2013
      • ALLERGY AND COLD
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: Allergy and Cold Treatments (in millions of dollars at the manufacturers level)
      • ANTILIPIDEMIC AGENTS
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: Antilipidemic Agents (in millions of dollars at the manufacturers level)
      • FUNGAL INFECTIONS
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: Fungal Infection Treatments (in millions of dollars at the manufacturers level)
      • GASTROINTESTINAL
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: Gastrointestinal Treatments (in millions of dollars at the manufacturers level)
      • HAIR LOSS TREATMENT
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: Hair Loss Treatments (in millions of dollars at the manufacturers level)
      • MIGRAINE THERAPY
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: Migraine Therapies (in millions of dollars at the manufacturers level)
      • NSAIDS
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: NSAIDs (in millions of dollars at the manufacturers level)
      • ORAL CONTRACEPTIVES
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: Oral Contraceptives (in millions of dollars at the manufacturers level)
      • OSTEOPOROSIS AND HORMONE REPLACEMENT THERAPY
        • Market Analysis
      • OVERACTIVE BLADDER
        • Market Analysis
      • SEXUAL DYSFUNCTION
        • Viagra
        • Market Analysis
      • SLEEP AGENTS
        • Ambien
        • Lunesta
        • Provigil
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: Sleep Agents (in millions of dollars at the manufacturers level)
      • SMOKING CESSATION
        • Nicotrol Inhalation and Nasal Spray
        • Zyban
        • Market Analysis
          • Table Rx-to-OTC Market Analysis: Smoking Cessation (in millions of dollars at the manufacturers level)
      • VIRAL INFECTIONS
        • Tamiflu
        • Valtrex
        • Market Analysis
      • OTHERS
        • ReVia
        • Market Analysis
    • Issues and Trends Affecting the Rx-to-OTC Switch Industry
      • Table Leading Rx-to-OTC Switches 1994-2007
      • PROPOSED LEGISLATION
        • Table Health Insurance Trends in the United States 2003-2006
      • CONSUMERS AND RX-TO-OTC SWITCHES
      • DIRECT-TO-CONSUMER (DTC) ADVERTISING
      • PATIENT SAFETY
      • FDA AGAIN CONSIDERING THIRD CLASS OF MEDICINES
      • INSURANCE REIMBURSEMENT ISSUES
      • OTC SWITCH CRITERIA AND FDA INVOLVEMENT
      • COMPETITION STRATEGIES

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report